I-Mab Appoints New CEO to Drive Cancer Therapy Goals
Company Announcements

I-Mab Appoints New CEO to Drive Cancer Therapy Goals

I-MAB (IMAB) has released an update.

I-Mab, a global biotech firm focused on cancer immunotherapies, has appointed Sean Fu as its permanent CEO. With over 20 years in the life sciences industry, Fu aims to advance I-Mab’s clinical programs and strategy. His leadership is expected to drive the company towards significant milestones in the development of transformative therapies.

For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyI-Mab names Sean Fu as permanent CEO
TheFlyInhibrx prevails in trade secret case with I-Mab
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App